Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

124 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Carcinoma NCT00243347

- 25-01-17 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00243347

Eligibility Non Small Cell Lung Cancer (NSCLC) DRKS00005552 NCT00684385 - Eligibility Non Small Cell Lung Cancer (NSCLC) NCT00684385

- 30-07-16 - 1 Formulier, 2 Itemgroepen, 8 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT00684385

Eligibility Cancer of the Head and Neck NCT00180921

- 21-07-16 - 1 Formulier, 2 Itemgroepen, 14 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT00180921

Eligibility Head and Neck Squamous Cell Carcinoma NCT02143622

- 18-10-15 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02143622

Eligibility Head and Neck Cancer NCT01958515

- 31-08-15 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation; ODM derived from: https://clinicaltrials.gov/show/NCT01958515

Initial Evaluation Oropharyngeal Cancer RTOG 1016 I1NCT01302834

- 04-08-15 - 1 Formulier, 11 Itemgroepen, 85 Data-elementen, 1 Taal
Itemgroepen: Header Module, Patient demographics, Tumor Measurements At Presentation, Basis of Diagnosis, Laboratory Values, Primary Site, Staging, PRIOR TREATMENT, SEVERE ACTIVE COMORBIDITIES, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., Footer Module
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=94417A43-2D71-18EF-E040-BB89AD432749

NCT00265941 RTOG-0522 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form

- 08-07-15 - 1 Formulier, 18 Itemgroepen, 108 Data-elementen, 1 Taal
Itemgroepen: RTOG clinical trial administrative data, SUMMARY OF SYSTEMIC TREATMENT, INITIAL DOSE, WEEK 1 - DAY 1 - ACTUAL, WEEK 1 - DAY 1 - IDEAL, WEEK 2, WEEK 3, WEEK 4 - ACTUAL, WEEK 4 - IDEAL, WEEK 5, WEEK 6, WEEK 7, Off-protocol treatment, Protocol Specific Adverse Event Evaluation, Other Adverse Events, Lab Values Module, Make up doses #1-4, Comments
NCT00265941 RTOG-0522 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F62248A0-86B5-70AC-E034-0003BA3F9857

NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form

- 08-07-15 - 1 Formulier, 12 Itemgroepen, 67 Data-elementen, 1 Taal
Itemgroepen: RTOG clinical trial administrative data, Summary of Systemic Treatment, ARM 1 ONLY - DAY 1, DAY 22, Header, ARM 2 ONLY - WEEK 1 - INITIAL DOSE, WEEK 2-8, Non-Protocol Therapy, Tube feeding, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., New or continuing adverse events, Comments
NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9418B248-C31D-807C-E040-BB89AD431782

NCT00113399 RTOG-0421 COVER SHEET: Radiation Therapy Oncology Group Phase III Head and Neck Cover Sheet

- 08-07-15 - 1 Formulier, 2 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: RTOG clinical trial administrative data, Various questionnaire related information
NCT00113399 RTOG-0421 COVER SHEET: Radiation Therapy Oncology Group Phase III Head and Neck Cover Sheet Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EB7163DA-361E-5A04-E034-0003BA3F9857

RTOG-0522 AE: Adverse Event Evaluation Form NCT00265941

- 08-07-15 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: RTOG clinical trial administrative data, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
RTOG-0522 AE: Adverse Event Evaluation Form NCT00265941 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5E8260F-4A36-157F-E034-0003BA3F9857

RTOG-0421 AE: Adverse Event Evaluation Form NCT00113399

- 08-07-15 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: RTOG clinical trial administrative data, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
RTOG-0421 AE: Adverse Event Evaluation Form NCT00113399 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EB6FBB34-B48C-4885-E034-0003BA3F9857

NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form

- 08-07-15 - 1 Formulier, 9 Itemgroepen, 44 Data-elementen, 1 Taal
Itemgroepen: Header Module, Vital status, Tumor Measurements At Presentation, RECURRENCE OR PROGRESSION, New primary cancer, NON-PROTOCOL THERAPY, Protocol Specific Adverse Event Evaluation, New or continuing adverse events, Comments
NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9550D538-F61F-EAB4-E040-BB89AD4377BB

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial